As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

Here are my " Top 10 Investment Themes for 2026" for your review and consideration, many of which follow my overarching macro ...

ExploRNA Therapeutics’ biologically inspired, ground-breaking technologies are enabling more precise customization of mRNA constructs with advanced vaccine and therapeutic applications. Research based ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

PYC Therapeutics Limited ( ($AU:PYC) ) has shared an announcement. PYC Therapeutics has issued 2,000,000 unlisted options to director Peter ...

The interaction between genetics and tissue environment shapes how individual teeth form in different regions of the jaw.

Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

Death cap mushrooms (Amanita phalloides) are among the world’s most poisonous fungi, responsible for the majority of fatal ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Researchers in Beijing have generated a transcriptomic atlas comparing human fetal tooth germs from the upper and lower jaws at the critical cap stage of development. Previous studies of tooth ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.